The circadian gene NPAS2 is a novel prognostic biomarker for breast cancer

Breast Cancer Research and Treatment

Volumn 120, Issue 3, 2010, Pages 663-669

  Yi, Chunhui ^a   Mu, Lina ^a   De La Rigault Longrais, Irene A ^b   Sochirca, Olga ^b   Arisio, Riccardo ^c   Yu, Herbert ^a   Hoffman, Aaron E ^a   Zhu, Yong ^a   Katsaro, Dionyssios ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TURIN   (Italy)

^c S ANNA HOSPITAL   (Italy)

Author keywords

Circadian gene; Npas2 breast caner; Survival

Indexed keywords

ALANINE; GENE PRODUCT; NEURONAL PAS DOMAIN PROTEIN 2; THREONINE; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER STAGING; CANCER TISSUE; CIRCADIAN RHYTHM; DISEASE FREE SURVIVAL; DISEASE MARKER; DISEASE SEVERITY; DNA EXTRACTION; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; ADULT; AGED; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BREAST NEOPLASMS; CIRCADIAN RHYTHM; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GENOTYPE; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM PROTEINS; NERVE TISSUE PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RNA, MESSENGER; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 77950867308     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0484-0     Document Type: Article

References (27)

1. 1. Vansteensel MJ, Michel S, Meijer JH (2008) Organization of cell and tissue circadian pacemakers: a comparison among species. Brain Res Rev 58:18-47 (Pubitemid 351852926)
2. Kohsaka A, Bass J (2007) A sense of time: how molecular clocks organize metabolism. Trends Endocrinol Metab 18:4-11 (Pubitemid 44960013)
3. Ko CH, Takahashi JS (2006) Molecular components of the mammalian circadian clock. Hum Mol Genet 15(Spec No 2):R271R277
4. Kaeffer B, Pardini L (2005) Clock genes of mammalian cells: practical implications in tissue culture. In Vitro Cell Dev Biol Anim 41:311-320
5. Zhou YD, Barnard M, TianH, LiX, RingHZ, Francke U, Shelton J, Richardson J, Russell DW, McKnight SL (1997) Molecular characterization of two mammalian bHLH-PAS domain proteins selectively expressed in the central nervous system. Proc Natl Acad Sci U S A 94:713-718 (Pubitemid 27053699)
6. Gilles-Gonzalez MA, Gonzalez G (2004) Signal transduction by heme-containing PAS-domain proteins. J Appl Physiol 96:774783
7. Chen-Goodspeed M, Lee CC (2007) Tumor suppression and circadian function. J Biol Rhythms 22:291-298
8. Reick M, Garcia JA, Dudley C, McKnight SL (2001) NPA.S2: an analog of clock operative in the mammalian forebrain. Science 293: 506-509 (Pubitemid 32679079)
9. Vitaterna MH, King DP, Chang AM, Kornhauser JM, Lowrey PL, McDonald JD, Dove WF, Pinto LH, Turek FW, Takahashi JS ( 1994) Mutagenesis and mapping of a mouse gene, clock, essential for circadian behavior. Science 264:719-725
10. Bunger MK, Wilsbacher LD, Moran SM, Clendenin C, Radcliffe LA, Hogenesch JB, Simon MC, Takahashi JS, Bradfield CA (2000) Mop3 is an essential component of the master circadian pacemaker in mammals. Cell 103:1009-1017 (Pubitemid 32037390)
11. Fu L, Pelicano H, Liu J, Huang P, Lee C (2002) The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111:41-50
12. Hoffman AE, Zheng T, Ba Y, Zhu Y (2008) The circadian gene NPAS2, a putative tumor suppressor, is involved in DNA damage response. Mol Cancer Res 6:1461-1468
13. Zhu Y, Leaderer D, Guss C, Brown HN, Zhang Y, Boyle P, Stevens RG, Hoffman A, Qin Q, Han X, Zheng T (2007) Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin's lymphoma. Int J Cancer 120:432-435
14. Zhu Y, Stevens RG, Leaderer D, Hoffman A, Holford T, Zhang Y, Brown HN, Zheng T (2008) Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk. Breast Cancer Res Treat 107:421-425
15. Chu LW, Zhu Y, Yu K, Zheng T, Yu H, Zhang Y, Sesterhenn I, Chokkalingam AP, Danforth KN, Shen MC, Stanczyk FZ, Gao YT, Hsing AW (2008) Variants in circadian genes and prostate cancer risk: a population-based study in China. Prostate Cancer Prostatic Dis 11:342-348
16. Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, Chang JG (2005) Deregulated expression of the PERl, PER2 and PER3 genes in breast cancers. Carcinogenesis 26:1241-1246
17. Winter SL, Bosnoyan-Collins L, Pinnaduwage D, Andrulis IL (2007) Expression of the circadian clock genes Perl, and Per2 in sporadic and familial breast tumors. Neoplasia 9:797-800 (Pubitemid 47623419)
18. Tokunaga H, Takebayashi Y, Utsunomiya H, Akahira JI, Higashimoto M, Mashiko M, Ito K, Niikura H, Takenoshita SI, Yaegashi N (2008) Clinicopathological significance of circadian rhythm-related gene expression levels in patients with epithelial ovarian cancer. Acta Obstet Gynecol Scand: 1-11
19. Sobin LH, Fleming ID (1997) TNM Classification of Malignant Tumors, fifth edition. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer, 80:1803-1804
20. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229-235 (Pubitemid 44631925)
21. Choi JY, Lee KM, Park SK, Noh DY, Ahn SH, Chung HW, Han W, Kim JS, Shin SG, Jang IJ, Yoo KY, Hirvonen A, Kang D (2005) Genetic polymorphisms of SULT1A1 and SULTlE1 and the risk and survival of breast cancer. Cancer Epidemiol Biomarkers Prev 14:1090-1095 (Pubitemid 40656452)
22. Mukaiyama Y, Uchida T, Sato E, Sasaki A, Sato Y, Igarashi J, Kurokawa H, Ságami I, Kitagawa T, Shimizu T (2006) Spectroscopic and DNA-binding characterization of the isolated hemebound basic helix-loop-helix-PAS-A domain of neuronal PAS protein 2 (NPAS2), a transcription activator protein associated with circadian rhythms. FEBS J 273:2528-2539 (Pubitemid 43736664)
23. Lin YM, Chang JH, Yeh KT, Yang MY, Liu TC, Lin SF, Su WW, Chang JG (2008) Disturbance of circadian gene expression in hepatocellular carcinoma. Mol Carcinog 47:925-933
24. Lee CC (2006) Tumor suppression by the mammalian Period genes. Cancer Causes Control 17:525-530
25. Hua H, Wang Y, Wan C, Liu Y, Zhu B, Wang X, Wang Z, Ding JM (2007) Inhibition of tumorigenesis by intratumoral delivery of the circadian gene mPer2 in C57BL/6 mice. Cancer Gene Ther 14:815-818 (Pubitemid 47262754)
26. Hua H, Wang Y, Wan C, Liu Y, Zhu B, Yang C, Wang X, Wang Z, Cornelissen-Guillaume G, Halberg F (2006) Circadian gene mPer2 overexpression induces cancer cell apoptosis. Cancer Sci 97:589-596 (Pubitemid 44056606)
27. Garcia-Saenz JA, Martin M, Maestro M, Vidaurreta M, Veganzones S, Villalobos L, Rodriguez-Lajusticia L, Rafael S, SanzCasla MT, Casado A, Sastre J, Arroyo M, Diaz-Rubio E (2006) Circulating tumoral cells lack circadian-rhythm in hospitalized metastasic breast cancer patients. Clin Transi Oncol 8:826-829